BRPI0614961A2 - aptâmero, método, e, composição - Google Patents

aptâmero, método, e, composição

Info

Publication number
BRPI0614961A2
BRPI0614961A2 BRPI0614961A BRPI0614961A BRPI0614961A2 BR PI0614961 A2 BRPI0614961 A2 BR PI0614961A2 BR PI0614961 A BRPI0614961 A BR PI0614961A BR PI0614961 A BRPI0614961 A BR PI0614961A BR PI0614961 A2 BRPI0614961 A2 BR PI0614961A2
Authority
BR
Brazil
Prior art keywords
aptamer
composition
Prior art date
Application number
BRPI0614961A
Other languages
English (en)
Inventor
David Fontana
Jess Wagner-Whyte
John L Diener
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Publication of BRPI0614961A2 publication Critical patent/BRPI0614961A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
BRPI0614961A 2005-08-26 2006-08-23 aptâmero, método, e, composição BRPI0614961A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71176805P 2005-08-26 2005-08-26
US80859006P 2006-05-26 2006-05-26
PCT/US2006/033092 WO2007025049A2 (en) 2005-08-26 2006-08-23 Aptamers that bind thrombin with high affinity

Publications (1)

Publication Number Publication Date
BRPI0614961A2 true BRPI0614961A2 (pt) 2016-09-13

Family

ID=37772390

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614961A BRPI0614961A2 (pt) 2005-08-26 2006-08-23 aptâmero, método, e, composição

Country Status (12)

Country Link
US (2) US7998939B2 (pt)
EP (1) EP1928505A4 (pt)
JP (1) JP2009508473A (pt)
KR (1) KR20080042091A (pt)
AU (1) AU2006283025A1 (pt)
BR (1) BRPI0614961A2 (pt)
CA (1) CA2617782A1 (pt)
EA (1) EA200800667A1 (pt)
IL (1) IL188797A0 (pt)
ME (2) ME00016B (pt)
RS (1) RS20080075A (pt)
WO (1) WO2007025049A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134069A2 (en) * 2007-04-26 2008-11-06 University Of Florida Research Foundation Anchored ligand agents
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
US20110275701A1 (en) * 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
US10231993B2 (en) * 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
BR102013021701A2 (pt) 2013-08-26 2015-07-28 Univ São Paulo Usp Polinucleotídeos quimicamente modificados e processo de produção de polinucleotídeos quimicamente modificados
KR20170055474A (ko) * 2014-07-31 2017-05-19 아카데미아 시니카 길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
IL234246A0 (en) 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2021113696A1 (en) * 2019-12-04 2021-06-10 Duke University Methods for controlling extracorporeal membrane oxygenation (ecmo) coagulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1456092A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
WO2003070984A1 (en) * 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
AU2003297682A1 (en) 2002-12-03 2004-06-23 Archemix Corporation Method for in vitro selection of 2'-substituted nucleic acids
US20050037394A1 (en) 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
CN101208437B (zh) * 2003-12-12 2012-07-04 圣路易斯大学 检测大分子和其它分析物的生物传感器
EP1942911A4 (en) 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
AU2006302022A1 (en) 2005-10-06 2007-04-19 University Of Delaware G-rich polynucleotides for the treatment of Huntington's Disease

Also Published As

Publication number Publication date
US7998939B2 (en) 2011-08-16
EA200800667A1 (ru) 2008-08-29
RS20080075A (en) 2009-07-15
AU2006283025A1 (en) 2007-03-01
US20120149764A1 (en) 2012-06-14
IL188797A0 (en) 2008-08-07
EP1928505A2 (en) 2008-06-11
MEP0208A (xx) 2010-02-10
EP1928505A4 (en) 2010-10-27
ME00016B (me) 2010-06-10
WO2007025049A3 (en) 2009-04-16
CA2617782A1 (en) 2007-03-01
WO2007025049A2 (en) 2007-03-01
JP2009508473A (ja) 2009-03-05
US20090221680A1 (en) 2009-09-03
KR20080042091A (ko) 2008-05-14

Similar Documents

Publication Publication Date Title
BRPI0614961A2 (pt) aptâmero, método, e, composição
BRPI0809573A2 (pt) composição, e, método
BRPI0919575A2 (pt) método, e, composição
BRPI0918170A2 (pt) método, e, composição endurecível
BRPI0809690A2 (pt) Composição de lubrificante, e, método
BRPI0823277A2 (pt) Composição, e , método
BRPI0814167A2 (pt) Composição, e, método
NO20055686D0 (no) Sammensetning
DE602007005963D1 (de) Relaisknoten und -verfahren
DE502005007322D1 (de) Einpresskontakt
BRPI0815922A2 (pt) Artigo, composição, e, método.
DE602006018129D1 (de) Codierer, decodierer und verfahren dafür
BRPI0823238A2 (pt) Composição, e, método
BRPI0717073A2 (pt) Composição detergente e método
DE602006012689D1 (de) Überprüfungsverfahren
BRPI0718068A2 (pt) Material compósito, e, método
FI20055682A0 (fi) Läpivientiosa sekä menetelmä
BRPI0715167A2 (pt) Composição e método de desfolhante
BRPI0906465A2 (pt) Composição efervesente, e, método
DK1955066T3 (da) Membran-assay-fremgangsmåde
FI20050681A0 (fi) Paikoitusmenetelmä
BRPI0822856A2 (pt) Composição, e, método
BRPI0613947A2 (pt) conjunto, e, pneumático
DE102005012312B8 (de) Montagelinie und -verfahren
ITBO20050198A1 (it) Metodo e impianto

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO 020080028179/RJ DE 25/02/2008.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.